MARKET

BFRIW

BFRIW

BIOFRONTERA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.570
-0.091
-5.46%
Closed 16:00 01/14 EST
OPEN
1.680
PREV CLOSE
1.661
HIGH
1.930
LOW
1.500
VOLUME
280.97K
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
0.7001
MARKET CAP
--
P/E (TTM)
-1.2057
1D
5D
1M
3M
1Y
5Y
Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter a...
GlobeNewswire · 3d ago
Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January
WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that it plans to participate in the following tw...
GlobeNewswire · 6d ago
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
WOBURN, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced that through the exercise of outstanding warrants the majority ownersh...
GlobeNewswire · 12/30/2021 13:45
BRIEF-Biofrontera Inc Files Prospectus Relates To Offering And Resale, From Time To Time By Selling Stockholder Of Up To 5.7 Million Shares Of Common Stock
reuters.com · 12/21/2021 22:25
BRIEF-Biofrontera Announces Enrollment Of First Subject In Phase 2B Clinical Trial Evaluating Ameluz + Bf-Rhodoled In Moderate-To-Severe Acne
reuters.com · 12/13/2021 14:52
Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has i...
GlobeNewswire · 12/08/2021 14:32
BRIEF-Biofrontera Inc Enrolls First Subject In Phase 1 Safety Study Evaluating Photodynamic Therapy With Three Tubes Of Ameluz®
reuters.com · 12/06/2021 14:34
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in a Phase 1 study to e...
GlobeNewswire · 12/06/2021 14:00
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BFRIW. Analyze the recent business situations of BIOFRONTERA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About BFRIW
Biofrontera Inc is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

Webull offers kinds of Biofrontera Inc stock information, including NASDAQ:BFRIW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRIW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BFRIW stock methods without spending real money on the virtual paper trading platform.